NLS merger partner Kadimastem secures Hong Kong patent for diabetes therapy
PositiveFinancial Markets
Kadimastem has successfully secured a patent in Hong Kong for its innovative diabetes therapy, marking a significant milestone in its efforts to combat the disease.
Editor’s Note: This patent is crucial as it not only protects Kadimastem's intellectual property but also enhances its credibility and potential for growth in the diabetes treatment market, which is vital for millions of patients worldwide.
— via World Pulse Now AI Editorial System